Gao Zhenya, Jia Huanxia, Yu Fang, Guo Hongfang, Li Baoyu
Department of Clinical Medicine, School of Medicine, Xuchang University, Xuchang, Henan 461000, P.R. China.
Department of General Surgery, The Secondary Hospital of Tianjin Medical University, Tianjin 300211, P.R. China.
Exp Ther Med. 2021 Oct;22(4):1094. doi: 10.3892/etm.2021.10528. Epub 2021 Aug 2.
Hepatocellular carcinoma (HCC) is one of the most common malignancies with high mortality and morbidity rates. In recent years, HCC targeted therapy has gained increasing attention. Due to the heterogeneity and high metastasis of HCC, more effective therapeutic targets are needed. Kinesin family member 2C (KIF2C), also known as mitotic centromere-associated kinesin, is a microtubule-based motor protein which is involved in a variety of important cellular processes, such as mitosis. The effects of KIF2C on cancer progression and development have been widely studied; however, its potential effects on HCC remains unclear. In the present study, high expression of KIF2C in human HCC tissues was demonstrated using The Cancer Genome Atlas database and immunohistochemistry assays. KIF2C expression was associated with HCC prognosis, including overall survival and disease-free survival. KIF2C expression was also associated with clinical pathological characteristics including the number of tumor nodes (P=0.015) and tumor size (P=0.009). KIF2C knockdown inhibited the proliferation of HCC cells , confirmed by MTT and colony formation assays, and suppressed tumor growth in mice which was confirmed by a xenograft mouse model. Together, the results suggested that KIF2C may serve as a promising therapeutic target for the treatment of HCC.
肝细胞癌（HCC）是最常见的恶性肿瘤之一，死亡率和发病率都很高。近年来，HCC靶向治疗越来越受到关注。由于HCC的异质性和高转移性，需要更有效的治疗靶点。驱动蛋白家族成员2C（KIF2C），也称为有丝分裂着丝粒相关驱动蛋白，是一种基于微管的驱动蛋白，参与多种重要的细胞过程，如有丝分裂。KIF2C对癌症进展和发展的影响已得到广泛研究；然而，其对HCC的潜在影响仍不清楚。在本研究中，使用癌症基因组图谱数据库和免疫组织化学分析证明了KIF2C在人HCC组织中的高表达。KIF2C表达与HCC预后相关，包括总生存期和无病生存期。KIF2C表达还与临床病理特征相关，包括肿瘤结节数量（P = 0.015）和肿瘤大小（P = 0.009）。MTT和集落形成试验证实，KIF2C敲低抑制了HCC细胞的增殖，异种移植小鼠模型证实其抑制了小鼠肿瘤生长。总之，结果表明KIF2C可能是治疗HCC的一个有前景的治疗靶点。
